1676 related articles for article (PubMed ID: 19436038)
1. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
2. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
5. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
6. Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.
de Macêdo Andrade AC; Ferreira Júnior CA; Dantas Guimarães B; Pessoa Barros AW; Sarmento de Almeida G; Weller M
BMC Womens Health; 2014 Sep; 14():110. PubMed ID: 25216732
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
8. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
9. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
[TBL] [Abstract][Full Text] [Related]
10. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer.
Chen X; Sun L; Mao Y; Zhu S; Wu J; Huang O; Li Y; Chen W; Wang J; Yuan Y; Fei X; Jin X; Shen K
BMC Cancer; 2013 Aug; 13():390. PubMed ID: 23957561
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
14. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
[TBL] [Abstract][Full Text] [Related]
15. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors for Luminal B-like Breast Cancer.
Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
[TBL] [Abstract][Full Text] [Related]
17. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
18. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
[TBL] [Abstract][Full Text] [Related]
19. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Bago-Horvath Z; Rudas M; Singer CF; Greil R; Balic M; Lax SF; Kwasny W; Hulla W; Gnant M; Filipits M
Clin Cancer Res; 2020 Nov; 26(21):5682-5688. PubMed ID: 32546648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
